Comparative Pharmacology
Head-to-head clinical analysis: POLYCILLIN N versus POLYCILLIN PRB.
Peer-Reviewed Evidence
Head-to-head clinical analysis: POLYCILLIN N versus POLYCILLIN PRB.
POLYCILLIN-N vs POLYCILLIN-PRB
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ampicillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking, and activating autolytic enzymes. It is bactericidal against susceptible organisms.
POLYCILLIN-PRB combines ampicillin and probenecid. Ampicillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). Probenecid inhibits renal tubular secretion of ampicillin, increasing its plasma concentration.
1-2 g IV/IM every 4-6 hours
250-500 mg orally every 6 hours or 500 mg-1 g intramuscularly every 6-8 hours.
None Documented
None Documented
Terminal elimination half-life: 0.5-1 hour (normal renal function); increases to 7-10 hours in anuria. Prolonged in neonates (2-4 hours).
Terminal elimination half-life: 1-1.5 hours in patients with normal renal function; prolonged to 7-10 hours in anuria.
Renal: 60-80% unchanged via glomerular filtration and tubular secretion. Biliary: ~20% excreted in bile and feces. Small amount metabolized to penicilloic acid.
Renal: 60-80% unchanged via glomerular filtration and tubular secretion; Biliary/fecal: 20-40% as metabolites and unchanged drug.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic